Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang Fang

Showing results (291-300 of 300) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 300 results.
Biorxiv : the Preprint Server for Biology|November 1, 2024
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancerChing-Fei Li, Li-Yuan Bai, Yongkun Wei, et al.
International Journal of Medical Sciences|March 1, 2014
The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in TaiwanTsung-Hsien Lin, Shao-Yuan Chuang, Chun-Yuan Chu, et al.
JAMA Oncology|December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical TrialTom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
Journal of Clinical Medicine|March 29, 2023
Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in TaiwanPatrick Yan-Tyng Liu, Fang-Ju Lin, Chih-Fan Yeh, et al.
Biomedical Journal|August 14, 2023
A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation studyYu-Chung Hsiao, Thung-Lip Lee, Fang-Ju Lin, et al.
Journal of Hepatology|September 19, 2025
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker explorationYih-Jyh Lin, Da-Liang Ou, Yung-Yeh Su, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Lancet (London, England)|January 11, 2025
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, et al.
Cancer Letters|July 12, 2025
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in TaiwanShao-Chun Wang, Yi-Chun Shen, Mei-Ren Pan, et al.
The New England Journal of Medicine|December 27, 2013
Variant GADL1 and response to lithium therapy in bipolar I disorderChien-Hsiun Chen, Chau-Shoun Lee, Ming-Ta Michael Lee, et al.
Pageof 30

Showing results (291-300 of 300) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 300 results.
Biorxiv : the Preprint Server for Biology|November 1, 2024
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancerChing-Fei Li, Li-Yuan Bai, Yongkun Wei, et al.
International Journal of Medical Sciences|March 1, 2014
The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in TaiwanTsung-Hsien Lin, Shao-Yuan Chuang, Chun-Yuan Chu, et al.
JAMA Oncology|December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical TrialTom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
Journal of Clinical Medicine|March 29, 2023
Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in TaiwanPatrick Yan-Tyng Liu, Fang-Ju Lin, Chih-Fan Yeh, et al.
Biomedical Journal|August 14, 2023
A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation studyYu-Chung Hsiao, Thung-Lip Lee, Fang-Ju Lin, et al.
Journal of Hepatology|September 19, 2025
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker explorationYih-Jyh Lin, Da-Liang Ou, Yung-Yeh Su, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Lancet (London, England)|January 11, 2025
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, et al.
Cancer Letters|July 12, 2025
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in TaiwanShao-Chun Wang, Yi-Chun Shen, Mei-Ren Pan, et al.
The New England Journal of Medicine|December 27, 2013
Variant GADL1 and response to lithium therapy in bipolar I disorderChien-Hsiun Chen, Chau-Shoun Lee, Ming-Ta Michael Lee, et al.
Pageof 30